Abstract
Accurately predicting inhibitor-kinase binding affinity is crucial in drug discovery and medical applications, especially in the treatment of diseases such as cancer. Existing methods for predicting inhibitor-kinase affinity still face challenges, including insufficient data expression, limited feature extraction, and low performance. Despite the progress made through artificial intelligence methods, particularly deep learning technology, many current methods fail to capture the intricate interactions between kinases and inhibitors. Therefore, it is necessary to develop more advanced methods to solve the existing problems in inhibitor-kinase binding prediction. This study proposed Kinhibit, a novel framework for inhibitor-kinase binding affinity prediction. Kinhibit integrates self-supervised graph contrastive learning with multiview molecular graph representation and structure-informed protein language model (ESM-S) to extract features effectively. Kinhibit also employed a feature fusion approach to optimize the fusion of inhibitor and kinase features. Experimental results demonstrate the superiority of this method, achieving an accuracy of 92.6% in inhibitor prediction tasks of three mitogen-activated protein kinase (MAPK) signalling pathway kinases: Raf protein kinase (RAF), Mitogen-activated protein kinase kinase (MEK), and Extracellular Signal-Regulated Kinase (ERK). Furthermore, the framework achieves an impressive accuracy of 92.9% on the MAPK-All dataset. This study provides promising and effective tools for drug screening and biological sciences.